Benzinga | Aug 5, 2021 07:44AM EDT

Aclaris Therapeutics Q2 EPS $(0.34) Down From $(0.28) YoY, Sales $1.82M Down From $2.05M YoY

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.34) per share. This is a 21.43 percent decrease over losses of $(0.28) per share from the same period last year. The company reported $1.82 million in sales this quarter. This is a 10.85 percent decrease over sales of $2.05 million the same period last year.